Eunoe CogniShunt
This article was originally published in The Gray Sheet
Executive Summary
Commencement of 256-patient, 25-site, pivotal Phase III U.S. trial of the device to treat Alzheimer's disease is announced Nov. 12. The implanted shunt is designed to increase the flow of cerebrospinal fluid and improve clearance of potential neurotoxins from the fluid surrounding the brain. By removing the neurotoxins from the CSF fluid, the firm believes it may be possible to halt progression of Alzheimer's...